Register for free to listen to this article
Listen with Speechify
0:00
1:00
PUNE, India—Life science and healthcare IT consulting company Optra Systems announced in December it has joined the Microsoft Bio-IT Alliance, an association of life science organizations and informatics companies whose focus is to enhance collaboration and accelerate the pace of drug discovery and development. Optra develops complete workflow management tools, including image acquisition, storage, processing, analyzing and reporting. Other alliance members include Accelrys Software Inc., Affymetrix Inc., Agilent Technologies Inc., Amylin Pharmaceuticals Inc., Applied Biosystems, The BioTeam Inc., Digipede Technologies LLC, Discovery Biosciences Corp., Geospiza Inc., Hewlett-Packard Development Co. L.P., Illumina Inc., InterKnowlogy, Linguamatics Ltd., Microsoft Corp., Sun Microsystems Inc., The Scripps Research Institute and VizX Labs LLC. DDN

Related Topics

Published In

Volume 5 - Issue 1 | January 2009

January 2009

January 2009 Issue

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A blue x-ray style image of a human body is shown with the liver illuminated in orange against a dark blue background.

Harnessing liver-on-a-chip models for drug safety

Discover how researchers leverage microphysiological systems in toxicology studies.  
A person wearing a white lab coat types on a laptop with various overlaid enlarged files shown with plus signs on file folders floating over the laptop screen with a clinical lab shown in the background in grey and white tones.

Enhancing bioanalytical studies with centralized data management

Learn how researchers can improve compliance and efficiency with advanced LIMS solutions.
A 3D-rendered digital illustration of a molecular structure floating among red blood cells in a bloodstream environment.

Explained: How are metabolite biomarkers improving drug discovery and development?

By offering a rich source of insights into disease and drugs, metabolite biomarkers are at the forefront of therapeutic exploration.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue